Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) Nexus 2018
Drug Market to See More Competition, Launch of Biosimilars in 2019
October 23, 2018
Dr Aimee Tharaldson Outlines Current Key Market Trends in Specialty Pharmacy
October 23, 2018
Dr Jane F. Barlow: How Curative, High-Cost Therapies Bring Challenges to the Reimbursement Landscape
October 23, 2018
Law to Curb Opioid Abuse Will Have Many Managed Care Priorities, Experts Say
October 23, 2018
Analysis Finds HIV Therapy Biktarvy Associated With Cost Savings Compared With Most Regimens
October 24, 2018
Dr Christopher Diehl Explains the Pharmacist's Role in Value-Based Models
October 24, 2018
Dr Jennifer Graff on Using Real-World Evidence to Deliver High-Quality Care
October 24, 2018
CMS Audits Give View Into How Well Health Plans Deliver Medicare Programs
October 24, 2018
Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS
October 25, 2018
Dan Mendelson: Healthcare Policy Changes Avalere Health Is Paying Attention To
October 25, 2018
Dr Kibum Kim on Precision Medicine in Managed Care
October 25, 2018
From Pathways to Pharmacy: Sharing Approaches to Value-Based Care
October 25, 2018
Dr Jane F. Barlow on How Curative, High-Cost Therapies Will Affect Patient OOP Costs
November 09, 2018
Dr Aimee Tharaldson: Recently Approved Specialty Drugs, Upcoming Approvals to Watch For
November 13, 2018
Dan Mendelson Discusses How Mergers and Acquisitions Are Affecting the Market
November 14, 2018
Dan Mendelson on the Trump Administration's Efforts to Lower Drug Prices
November 22, 2018
Dr Jane F. Barlow Discusses Potential New Reimbursement Models for New, High-Cost Therapies
November 27, 2018
Dan Mendelson's Expectations for Cross-Sector Mergers Like CVS, Aetna
November 28, 2018
Currently Reading
Specialty Drug Approvals Dr Aimee Tharaldson is Looking Out for in 2019
November 29, 2018

Specialty Drug Approvals Dr Aimee Tharaldson is Looking Out for in 2019

Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, outlines specialty drug approvals she's keeping her eye on in the coming year.


Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, outlines specialty drug approvals she's keeping her eye on in the coming year.

Transcript

Are there any drug approvals that you are keeping your eye on in 2019?

So, as far as some drugs to watch for in 2019, there’s actually going to be 4 new oral medications for MS [multiple sclerosis]. I just want to highlight one of them: cladribine. This is a little different mechanism. It helps silence the immune function in the brain in patients with MS. It seems to be effective. What’s interesting about this medication is the dosing of it. It’s given once daily for 5 days one week, then a month later it’s given once daily for 5 days. That regimen’s repeated in year 2, and then that’s it. So, it’s very unique as far as how it’s administered, so that’ll be an interesting new option on the market for patients with relapsing MS.

Another gene therapy to watch for is AVXS-101. So, this is for patients with spinal muscular atrophy type 1. So, that only represents patients from birth to 6 months, and it’s a very severe form of muscular atrophy where these patients, who are babies, aren’t able to crawl or walk. They have difficulty breathing and eating. Only about 8% of babies diagnosed with this survive to 20 months of age, so there’s a need for treatment options for them. We do have spinraza, which is an intrathecal medication. It works differently. This is a once-time infusion gene therapy that has demonstrated strong efficacy in clinical trials. This could cost anywhere from $1 million to $3 million for a one-time infusion.

We also have tafamadis—an interesting drug to watch for in 2019, as well. This is for patients with cardiomyopathy due to transthyretin mediated amyloidosis. So this could be used in patients that have hereditary form of disease and wildtype, which just occurs as people age. When patients finally get this diagnosis—it takes a long time to diagnose these patients—their life expectancy is only about 3 to 5 years because they progress rapidly to atrial fibrillation and heart failure.

So, this is an oral medication. It’s going to approved next year to treat these patients, and it looks like it’s going to be a pretty effective medication in clinical trials. We saw a 30% reduction in mortality, as well as a 32% reduction in cardiovascular-related hospitalizations, as well. So, was for that, probably mid 2019.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up